NCT05261269View on ClinicalTrials.gov

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 2, 2022

Primary Completion Date

September 13, 2023

Study Completion Date

October 11, 2023

Conditions
HER2-negative Metastatic Breast Cancer
Interventions
DRUG

DAN-222

Administered IV every week to subjects

DRUG

Niraparib

Administered orally once daily

Trial Locations (9)

10029

Icahn School of Medicine at Mount Sinai, New York

15232

Magee Women's Hospital, Pittsburgh

33612

H Lee Moffitt Cancer Center and Research Institute, Tampa

37203

Sarah Cannon Research Institute/Tennessee Oncology, Nashville

48109

University of Michigan, Ann Arbor

64111

Saint Luke's Cancer Institute, Jackson

73104

The University of Oklahoma Health Sciences Center, Oklahoma City

90404

UCLA - Parkside Cancer Center, Santa Monica

92093

UC San Diego Moores Cancer Center, La Jolla

All Listed Sponsors
lead

Dantari, Inc.

INDUSTRY